Biochemical Investigations in Parkinsonism

Pullar, Ian A.; Dowson, J. H.; Ahmed, R.; Chow, Ronald; Gillingham, F. J.

doi:10.1159/000103047

Cited by 4 publications

(1 citation statement)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, many classical studies have shown variable degrees of decrease in the CSF HVA levels of PD patients compared with controls (Bernheimer et al, 1966; Guldberg et al, 1967; Johansson and Roos, 1967; Olsson and Roos, 1968; Gottfries et al, 1969; Curzon et al, 1970; van Woert and Bowers, 1970; Godwin-Austen et al, 1971; Mones et al, 1972; Papeschi et al, 1972; Pullar et al, 1972; Cox et al, 1973; Voto Bernales et al, 1973; Weiner and Klawans, 1973; Granerus et al, 1974; Davidson et al, 1977; Tabaddor et al, 1978; Lovenberg et al, 1979; Cunha et al, 1983; Mann et al, 1983; Cramer et al, 1984; Mena et al, 1984; Pezzoli et al, 1984; Burns et al, 1985; Gibson et al, 1985; Jolkkonen et al, 1986; Liu, 1989; Hartikainen et al, 1992; Strittmatter and Cramer, 1992; Chia et al, 1993; Mashige et al, 1994; Eldrup et al, 1995; Cheng et al, 1996; Strittmatter et al, 1996; Kanemaru et al, 1998; Goldstein et al, 2008). Engelborghs et al (2003) reported normal CSF DA and HVA, and decreased DOPAC levels.…”

Section: Neurotransmitters Neuromodulators and Related Substancesmentioning

confidence: 99%

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds from the brain back to the bloodstream. In several neurodegenerative diseases, including Parkinson's disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with the aim of establishing useful biomarkers for an accurate differential diagnosis among these syndromes. This review article summarizes the studies reported on CSF levels of many potential biomarkers of PD. The most consistent findings are: (a) the possible role of CSF urate on the progression of the disease; (b) the possible relations of CSF total tau and phosphotau protein with the progression of PD and with the preservation of cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a useful marker of further cognitive decline in PD patients, and (d) the potential usefulness of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with long-term follow-up and neuropathological confirmation would be useful in establishing appropriate biomarkers for PD.

show abstract

Section: Neurotransmitters Neuromodulators and Related Substancesmentioning

confidence: 99%

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

Neurochemical biomarkers in the differential diagnosis of movement disorders

Mollenhauer

Trenkwalder

2009

Movement Disorders

View full text Add to dashboard Cite

In recent years, the neurochemical analysis of neuronal proteins in cerebrospinal fluid (CSF) has become increasingly accepted for the diagnosis of neurodegenerative dementia diseases such as Alzheimer's disease and Creutzfeldt-Jakob disease. CSF surrounds the central nervous system, and in the composition of CSF proteins one finds brain-specific proteins that are prioritized from blood-derived proteins. Levels of specific CSF proteins could be very promising biomarkers for central nervous system diseases. We need the development of more easily accessible biomarkers, in the blood. In neurodegenerative diseases with and without dementia, studies on CSF and blood proteins have investigated the usefulness of biomarkers in differential diagnosis. The clinical diagnoses of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration still rely mainly on clinical symptoms as defined by international classification criteria. In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF alpha-synuclein findings).

show abstract

Amine accumulation in Parkinson's disease and other disorders

Willis

1987

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Biochemical Investigations in Parkinsonism

Cited by 4 publications

References 2 publications

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Neurochemical biomarkers in the differential diagnosis of movement disorders

Amine accumulation in Parkinson's disease and other disorders

Contact Info

Product

Resources

About